Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 20, 2015, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.57 to $48,050,000.00.

Highlighted Stocks Traded by Insiders:

Harris & Harris Group (TINY) - FREE Research Report

Ramsey Charles E, who is Director at Harris & Harris Group, bought 2,065 shares at $3.01 on March 20, 2015. Following this transaction, the Director owned 85,594 shares meaning that the stake was boosted by 2.47% with the 2,065-share transaction.

Ayres W Dillaway JR, who is Director at Harris & Harris Group, bought 2,100 shares at $3.01 on March 20, 2015. Following this transaction, the Director owned 49,123 shares meaning that the stake was boosted by 4.47% with the 2,100-share transaction.

Shanley Richard P, who is Director at Harris & Harris Group, bought 2,780 shares at $3.01 on March 20, 2015. Following this transaction, the Director owned 59,401 shares meaning that the stake was boosted by 4.91% with the 2,780-share transaction.

Brandom Stacy, who is Director at Harris & Harris Group, bought 1,930 shares at $3.01 on March 20, 2015. Following this transaction, the Director owned 9,473 shares meaning that the stake was boosted by 25.59% with the 1,930-share transaction.

The shares most recently traded at $3.02, up $0.01, or 0.2% since the insider transaction. Historical insider transactions for Harris & Harris Group go as follows:

  • 4-Week # shares bought: 1,245
  • 12-Week # shares bought: 1,245
  • 24-Week # shares bought: 21,577

The average volume for Harris & Harris Group has been 98,300 shares per day over the past 30 days. Harris & Harris Group has a market cap of $94.5 million and is part of the financial sector and financial services industry. Shares are up 2.37% year-to-date as of the close of trading on Friday.

Harris & Harris Group, Inc. is a venture capital firm specializing in early stage investments. It is a BDC. Currently, there are no analysts who rate Harris & Harris Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TINY - FREE

TheStreet Quant Ratings

rates Harris & Harris Group as a

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and notable return on equity. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

Harris & Harris Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Universal Display (OLED) - FREE Research Report

Becker Leonard, who is Director at Universal Display, sold 5,000 shares at $46.02 on March 20, 2015. Following this transaction, the Director owned 35,000 shares meaning that the stake was reduced by 12.5% with the 5,000-share transaction.

The shares most recently traded at $45.95, down $0.07, or 0.15% since the insider transaction. Historical insider transactions for Universal Display go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 73,451
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 73,451
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 73,451

The average volume for Universal Display has been 748,100 shares per day over the past 30 days. Universal Display has a market cap of $2.0 billion and is part of the technology sector and computer hardware industry. Shares are up 60.07% year-to-date as of the close of trading on Friday.

Universal Display Corporation engages in the research, development, and commercialization of organic light emitting diode (OLED) technologies and materials for use in flat panel displays and solid-state lighting applications. The company has a P/E ratio of 49.2. Currently, there are 4 analysts who rate Universal Display a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OLED - FREE

TheStreet Quant Ratings

rates Universal Display as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Universal Display Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ligand Pharmaceuticals (LGND) - FREE Research Report

Patel Sunil, who is Director at Ligand Pharmaceuticals, sold 4,591 shares at $74.42 on March 20, 2015. Following this transaction, the Director owned 37,100 shares meaning that the stake was reduced by 11.01% with the 4,591-share transaction.

The shares most recently traded at $75.56, up $1.14, or 1.51% since the insider transaction. Historical insider transactions for Ligand Pharmaceuticals go as follows:

  • 4-Week # shares bought: 275
  • 4-Week # shares sold: 6,535
  • 12-Week # shares bought: 275
  • 12-Week # shares sold: 7,045
  • 24-Week # shares bought: 2,360
  • 24-Week # shares sold: 7,045

The average volume for Ligand Pharmaceuticals has been 315,200 shares per day over the past 30 days. Ligand Pharmaceuticals has a market cap of $1.5 billion and is part of the health care sector and drugs industry. Shares are up 44.15% year-to-date as of the close of trading on Friday.

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company has a P/E ratio of 135.3. Currently, there are 4 analysts who rate Ligand Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LGND - FREE

TheStreet Quant Ratings

rates Ligand Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, impressive record of earnings per share growth, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Ligand Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null